Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | Biomarker | disease | BEFREE | Coumarin- Fatty Acid Conjugates as Potential ERα/AKT-1 Antagonists for ER Positive Breast Cancer. | 31746305 | 2019 | ||||
|
0.090 | Biomarker | disease | BEFREE | These results underscore the critical role of estrogen-ERα as a modulator of the PI3K/AKT/mTOR signaling pathway in ER-positive breast cancer cells. | 31189691 | 2019 | ||||
|
0.090 | AlteredExpression | disease | BEFREE | Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. | 29507656 | 2018 | ||||
|
0.090 | GeneticVariation | disease | BEFREE | Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer. | 29482551 | 2018 | ||||
|
0.090 | GeneticVariation | disease | BEFREE | Both assays are employed at centralized testing laboratories operating according to quality standards for prospective identification of the AKT1 E17K mutation in ER+ breast cancer patients in the context of a clinical trial evaluating the AKT inhibitor AZD5363 in combination with endocrine (fulvestrant) therapy. | 28472036 | 2017 | ||||
|
0.090 | GeneticVariation | disease | BEFREE | We propose a randomized clinical trial to test whether the 31-gene AKT module could be used to identify estrogen receptor positive breast cancer patients who may benefit from therapy targeting the PI3K/AKT/mTOR signaling axis. | 25886003 | 2015 | ||||
|
0.090 | Biomarker | disease | BEFREE | Our results thus indicated that ER-α36-mediated antiestrogen signaling such as the PI3K/AKT plays an important role in antiestrogen resistance of ER-positive breast cancer stem/progenitor cells. | 25158023 | 2014 | ||||
|
0.090 | Biomarker | disease | BEFREE | BTG2 inhibits the expression of HER ligands and promotes AKT activation, which plays an essential role in the tamoxifen resistance of estrogen receptor (ER)-positive breast cancer. | 24698107 | 2014 | ||||
|
0.090 | Biomarker | disease | BEFREE | Knockdown of the tumor suppressor phosphatase Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) with shRNA in three estrogen receptor (ER)-positive breast cancer cell lines resulted in increased phosphatidylinositol-3 kinase (PI3K) and AKT activities, resistance to tamoxifen and fulvestrant, and hormone-independent growth. | 19435893 | 2009 |